Suchergebnisse - "Maher, T M"

PubPharm (39)

1

Can biomarkers of extracellular matrix remodelling and wound healing be used to identify high risk patients infected with SARS-CoV-2? : lessons learned from pulmonary fibrosis

enthalten in: Respiratory research | 2021

von Leeming, D. | Genovese, F. | Sand, J. | +6

2

Can biomarkers of extracellular matrix remodelling and wound healing be used to identify high risk patients infected with SARS-CoV-2?: lessons learned from pulmonary fibrosis

enthalten in: Respiratory research | 2021

von Leeming, D. | Genovese, F. | Sand, J. | +6

3

Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial : a randomised, double-blind, placebo-controlled, parallel-group trial

enthalten in: The Lancet. Respiratory medicine | 2020

von Wells, A. | Flaherty, K. | Brown, K. | +112

CommentIn: Lancet Respir Med. 2020 May;8(5):424-425. - PMID 32145831

4

Translational pharmacology of TD139, an inhaled small molecule galectin‐3 (Gal‐3) inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF)

enthalten in: The FASEB Journal | 2020

von Slack, R. | Hirani, N. | Gibbons, M. | +9

5

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

enthalten in: The New England journal of medicine | 2019

von Flaherty, K. | Wells, A. | Cottin, V. | +116

CommentIn: N Engl J Med. 2019 Oct 31;381(18):1775-1777. - PMID 31566308

6

A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK

enthalten in: PharmacoEconomics | 2017

von Rinciog, C. | Watkins, M. | Chang, S. | +4

7

A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK

enthalten in: PharmacoEconomics | 2016

von Rinciog, C. | Watkins, M. | Chang, S. | +4

8

A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK

enthalten in: PharmacoEconomics | 2016

von Rinciog, C. | Watkins, M. | Chang, S. | +4

9

A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK

enthalten in: PharmacoEconomics | 2016

von Rinciog, C. | Watkins, M. | Chang, S. | +4

10

Precision medicine in idiopathic pulmonary fibrosis

enthalten in: QJM : monthly journal of the Association of Physicians | 2016

von Maher, T.